Minervax Aps, the Denmark based biotech company, has raised EUR 54m in a funding round co-led by EQT Life Sciences Group (previously known as Life Sciences Partners Management (LSP)), the Netherlands based independent European investment firm, and OrbiMed Advisors, L.L.C., the US based healthcare-dedicated investment firm, with participation from Novo Holdings, Pureos Ventures, Sanofi Ventures, Trill Impact Ventures, Adjuvant Capital, Wellington Partners, Industrifonden, Sunstone LifeScience Ventures, and LF Invest.
Target – Minervax aps
Buyer – Wellington Partners Advisory AG
Buyer – Eqt Life Sciences Group b.v.
Buyer – Orbimed Advisors, l.l.c.
Buyer – Novo Holdings a/s
Buyer – Pureos Partners AG
Buyer – Sanofi ventures
Buyer – Trill Impact Ventures AB
Buyer – Adjuvant capital
Buyer – Industrifonden
Buyer – Lauritzen Fonden Holding aps
Buyer – Sunstone Life Science Ventures a/s
Seller – Shareholders
